The results are from an analysis of early-stage data from its COVID-19 vaccine, and one caveat is that the trial included just 20 adults aged 56 and older. However, those volunteers produced promising neutralizing antibodies, according to Moderna.
Moderna’s findings suggest older adults (ages 56 and up) and younger adults (ages 18-55) have similar immune responses to the vaccine.
Moderna’s vaccine, mRNA-1273, is currently in Phase 3 of human testing.
Meanwhile, the coronavirus has infected more than 23.9 million people globally. According to Johns Hopkins, the U.S. has surpassed 5.7 million cases with over 178,000 deaths.
Moderna’s stock jumped more than 5% on the news. The stock had more than tripled in 2020 through Tuesday.
The biotechnology company will present details about the new clinical data to the CDC’s Prevention’s Advisory Committee on Immunization Practices.
“This presentation will include new interim safety and immunogenicity data from the cohorts of older adults in the National-Institutes-of-Health-led Phase 1 study of mRNA-1273, Moderna’s vaccine candidate against Covid-19,” the Cambridge, Mass., company said in a statement.
Moderna's vaccine efforts are being funded by the U.S. federal government to the tune of about $955 million.